Pacritinib with a BTK inhibitor for mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of two targeted drugs (pacritinib plus a BTK inhibitor like ibrutinib) for people with mantle cell lymphoma that has come back or stopped responding to treatment. It may help if your current BTK inhibitor is no longer working well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have mantle cell lymphoma that came back or didn't respond after at least one prior treatment.
- You are currently taking a BTK inhibitor (like ibrutinib, acalabrutinib, or zanubrutinib) and it used to work but now the lymphoma is getting worse.
- Your cancer is measurable on a scan (for example, a lymph node at least 1.5 cm or a tumor at least 1 cm).
- Your overall health status is good (ECOG score of 2 or lower, meaning you can care for yourself or are up and about more than half the day).
- You have adequate blood cell counts (like neutrophils and platelets) and your kidney and liver functions are within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
This Phase 2 trial studies pacritinib, an oral medicine, for T-cell lymphoma/leukemia that has come back or did not respond to prior treatment. It aims to see how well pacritinib can control the cancer and improve outcomes.
This trial tests a combination of medicines to treat newly diagnosed high-risk mantle cell lymphoma (MCL). It may help shrink the lymphoma and improve outcomes, especially for people whose disease has higher-risk features.
This Phase 2 trial tests how well two anti-cancer medicines—glofitamab and pirtobrutinib—work for mantle cell lymphoma (MCL) that has not responded well to prior BTK inhibitor therapy. It may help by shrinking the lymphoma after earlier treatment and checking how safe the combination is for people with similar disease history.
This Phase 2 trial studies whether adding polatuzumab vedotin and rituximab to bendamustine (a chemotherapy combination) can help people with mantle cell lymphoma that has come back or is not responding after a BTK inhibitor (like ibrutinib, acalabrutinib, or zanubrutinib). If you qualify, you’ll be checked carefully to make sure your body can safely handle the treatment.
This trial tests a combination of two targeted drugs for people with mantle cell lymphoma that has come back or stopped responding after prior treatment with a BTK inhibitor. The goal is to see if this new combination can effectively shrink tumors.
Hear when a new Recurrent Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.